Nuvation Bio has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has validated the Marketing Authorisation Application (MAA) for taletrectinib, an investigational treatment for patients with advanced ROS1-positive (ROS1+) Non-Small Cell Lung Cancer (NSCLC). The application was submitted by the company's partner, Eisai, through the UK's International Recognition Procedure (IRP), an expedited regulatory pathway that considers approvals from trusted international regulatory authorities.

The validation marks the beginning of the MHRA's formal review process, during which the regulator will determine whether to approve taletrectinib for use in the UK.

The UK filing follows Nuvation Bio and Eisai's exclusive licensing and collaboration agreement signed in January 2026, covering Europe and several territories outside the US, China and Japan. Under the partnership, Eisai is responsible for expanding the global commercialisation of taletrectinib, which is already marketed as Ibtroz in the US and Japan. In March 2026, the European Medicines Agency (EMA) also validated the medicine's marketing application, while additional regulatory submissions were planned for Canada and other licensed territories.

According to the company, the UK records around 50,200 new lung cancer cases annually, with approximately 80–85 percent classified as NSCLC. Around 2 percent of these patients carry the ROS1-positive genetic mutation.

The regulatory application is supported by data from the pivotal Phase 2 TRUST-I and TRUST-II clinical studies evaluating taletrectinib in patients with advanced ROS1+ NSCLC. Findings from the pooled analysis were first published in the Journal of Clinical Oncology in April 2025, while updated efficacy and safety data were presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026. Updated results from the TRUST-I study were also published in the Journal of Clinical Oncology during the same month.

David Hung, Founder, President and Chief Executive Officer of Nuvation Bio, said the UK validation represents another important step in expanding patient access to taletrectinib globally. He noted that following approvals in the US, China and Japan, the company remains committed to making the treatment available to more patients worldwide.

Taletrectinib received full approval from the US Food and Drug Administration (FDA) in June 2025 for the treatment of adults with locally advanced or metastatic ROS1-positive NSCLC across treatment lines, following Priority Review and Breakthrough Therapy designations. The therapy is also approved in Japan, where it is marketed by Nippon Kayaku, and in China under the brand name Dovbleron, marketed by Innovent Biologics.

Globally, more than one million people are diagnosed with NSCLC each year, with approximately 2 percent carrying the ROS1-positive mutation. Around 35 percent of newly diagnosed metastatic ROS1+ patients present with brain metastases, while nearly half of previously treated patients eventually develop central nervous system disease progression.

Taletrectinib is an oral, next-generation, central nervous system-active ROS1 inhibitor designed to address both systemic and brain metastases. Nuvation Bio is continuing to evaluate the therapy through its global TRUST clinical programme, including ongoing Phase 3 studies assessing its efficacy in advanced and early-stage ROS1-positive NSCLC.